Tech Company Financing Transactions
Atreca Funding Round
Atreca closed a $125 million Series C funding round on 9/13/2018. Investors included Cormorant Asset Management, Wellington Management Company and Aisling Capital.
Transaction Overview
Company Name
Announced On
9/13/2018
Transaction Type
Venture Equity
Amount
$125,000,000
Round
Series C
Investors
Proceeds Purpose
This funding enables us to broaden and accelerate our discovery and pipeline generation efforts and to move our first candidate into clinical development.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
500 Saginaw Dr.
Redwood City, CA 94063
USA
Redwood City, CA 94063
USA
Phone
Website
Email Address
Overview
Atreca (Nasdaq: BCEL) develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Orwin
Chief Financial Officer
Susan Berland
Chief Information Officer
Wayne Volkmuth
Chief Scientific Officer
Norman Greenberg
Chief Technical Officer
Guy Cavet
VP - Bus. Development
Paulette Dillon
VP - Bus. Development
Tito Serafini
VP - Finance
Jonathan Woo
VP - R & D
Jonathan Benjamin
VP - R & D
Daniel Emerling
Browse more venture capital transactions:
Prev: 9/13/2018: Reprieve Cardiovascular venture capital transaction
Next: 9/13/2018: Integrate.ai venture capital transaction
Share this article
News on VC Transactions
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs